Compare Gilead Sciences, Inc. (GILD) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Global X Lithium & Battery Tech ETF trades at $69.02 (market cap $1.49B). The key difference: Gilead Sciences, Inc. is far larger — about 122.2× Global X Lithium & Battery Tech ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| GILD | LIT | |
|---|---|---|
Market Cap | $182.09B | $1.49B |
Volume | 4,960,247 | 67,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $91.62 |
52-Week Low | $116.74 | $53.92 |
Typical Hold Time | 111 Days | 56 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
LIT trades at $69.51, down 2.2% today amid mixed technical signals with a bullish overall rating but bearish moving averages and oscillators. The ETF's recent performance reflects volatility in lithium markets, with short interest dropping 53.1% in September. Key technical levels show support at $70 and resistance at $72. Recent news highlights ongoing EV sector growth with China targeting 30% NEV fleet by 2030, providing long-term tailwinds.
LIT offers exposure to the expanding battery technology sector with catalysts from EV adoption and energy storage demand. However, risks include lithium price volatility and Chinese export controls. The ETF's momentum is supported by semiconductor and AI-driven battery demand, though current technical indicators suggest near-term consolidation may precede further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
